Khan and colleagues [78] reported the synthesis of novel DHPM structures under sustainable conditions, and further test their inhibitory potential against cholinesterases (AChE and BChE) and monoamine oxidases A and B (MAO A and MAO B), common drug targets studied for the treatment of Alzheimer’s and Parkinson’s disease, depression, and anxiety. This evidence concerns the gene BCHE and depressive disorder.